Supplementary Online Content

Similar documents
Nilotinib AEs (adverse events) in CML population:

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:

Full Novartis CTRD Results Template

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Online Supplementary Data. Country Number of centers Number of patients randomized

Supplementary Online Content

HIGHLIGHTS OF PRESCRIBING INFORMATION

In first-line HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

Corporate Overview. May 2017 NASDAQ: CYTR

In HER2+ breast cancer: 2 INDICATIONS. PERJETA + Herceptin-based therapy dosing durations 1 CONTINUE UNTIL PROGRESSION OR UNACCEPTABLE TOXICITY

Clinical Trial Results Summary Study EN3409-BUP-305

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. Protein Kinase Inhibitor (L01XE23)

PRODUCT MONOGRAPH. Cabazitaxel for injection. Concentrated Solution 40 mg/ml (60 mg/1.5 ml) Antineoplastic Agent L01CD04

Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35

BR is an established treatment regimen for CLL in the front-line and R/R settings

Drafting a Coverage Authorization Request Letter

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

Supplementary Appendix

FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

For more information, call AstraZeneca Access 360 at ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET.

ICD-10 Physician Education. Palliative Care SIP

Celgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer

Full Novartis CTRD Results Template

Receiving PERJETA + Herceptinbased therapy * after surgery

PRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor

YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE

Recent advances in the management of metastatic breast cancer in older adults

Supplementary Appendix

Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Clinical Study Synopsis

Supplementary Online Content

Supplementary Online Content

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer

POMALYST (pomalidomide) for Previously Treated Multiple Myeloma

CONTRAINDICATIONS None (4)

FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT

Supplemental Table 1: Anti-Diabetic and Lipid Lowering Medications Before and 1 Year after Initiation of Metreleptin

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Supplementary Online Content

Reference ID:

FUJI study: Follow-Up of Jevtana in real life

HIGHLIGHTS OF PRESCRIBING INFORMATION

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

Taiwan PI for Velcade. (Followed as USPI version Jun 2017; Local version 1701)

Drug Niraparib Olaparib

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

Sponsor Novartis Pharma GmbH. Generic Drug Name Panobinostat (LBH589) Therapeutic Area of Trial Myelodysplastic Syndrome (MDS)

Episodes of Care Risk Adjustment

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Immune checkpoint blockade in lung cancer

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)

APR-DRG Description Ave Charge

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)

SCIENTIFIC DISCUSSION. London, 15 November 2007 EMEA/37144/2008 EMEA/H/C/000089/II/0045

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLĂ“GICOS HOSPITAL 12 DE OCTUBRE MADRID

DRUG NAME: Palbociclib

Tafinlar. Tafinlar (dabrafenib) Description

DRUG NAME: Palbociclib

Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN

MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc

Tafinlar. Tafinlar (dabrafenib) Description

SYNOPSIS. Clinical Study Report IM Double-blind Period

To report SUSPECTED ADVERSE REACTIONS, contact Millennium Pharmaceuticals at VELCADE or FDA at FDA-1088 or

PRODUCT MONOGRAPH. (docetaxel for injection) Concentrated Solution 80 mg/2.0 ml 20 mg/0.5 ml. Manufacturer s Standard. ATC code: L01C D02

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

CABAZITAXEL Prostate Cancer

Online-Only Supplementary Materials

BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT

PRODUCT MONOGRAPH. regorafenib tablets. 40 mg. Multikinase Inhibitor Antineoplastic

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

BRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:

Supplementary Online Content

Supplementary Online Content

NCCTG Status Report for Study N September 2007

GOG PROTOCOL #209. David Miller, MD, Gini Fleming, MD, Richard Zaino, MD, and David Cella, PhD

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008

A Study for Patients With Head and Neck Cancer

Supplementary Online Content

Transcription:

Supplementary Online Content Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol. Published online September 17, 2015. doi:10.1001/jamaoncol.2015.3101 etable 1. Distribution of Enrolled Patients by Country etable 2. Treatment-Emergent Adverse Events Occurring in 10% of Patients in Either Cohort etable 3. Serious Adverse Events Occurring in Any Patient in Either Cohort etable 4. Summary of Cardiac Events on Study This supplementary material has been provided by the authors to give readers additional information about their work.

etable 1. Distribution of Enrolled Patients by Country Country Number of Patients US 37 Romania 9 Hungary 26 Russia 16 Ukraine 10 Australia 15 India 13

etable 2. Treatment-Emergent Adverse Events Occurring in 10% of Patients in Either Cohort Aldoxorubicin (n=83) Doxorubicin (n=40) Number of patients (%) All grades Grade 3 or 4 All grades Grade 3 or 4 Any TEAE a 79 (95.2) 66 (79.5) 32 (80.0) 23 (57.5) Hematologic AE All grades Grade 3 or 4 All grades Grade 3 or 4 Anemia 36 (43.4) 14 (16.9) 13 (32.5) 8 (20.0) Neutropenia 33 (39.8) 24 (28.9) 7 (17.5) 5 (12.5) Leukopenia 15 (18.1) 8 (9.6) 4 (10.0) 2 (5.0) Febrile neutropenia 13 (15.7) 12 (14.5) 7 (17.5) 7 (17.5) Thrombocytopenia 11 (13.3) 7 (8.4) 6 (15.0) 2 (5.0) Nonhematologic AE All grades Grade 3 or 4 All grades Grade 3 or 4 Nausea 38 (45.8) 3 (3.6) 11 (27.5) Stomatitis 26 (31.3) 5 (6.0) 5 (12.5) 1 (2.5) Fatigue 24 (28.9) 3 (3.6) 6 (15.0) Alopecia 23 (27.7) 12 (30.0) Decreased appetite 20 (24.1) 3 (3.6) 2 (5.0) Vomiting 19 (22.9) 3 (3.6) 7 (17.5) Asthenia 15 (18.1) 2 (2.4) 5 (12.5) 1 (2.5) Pyrexia 14 (16.9) 1 (1.2) 3 (7.5) Constipation 12 (14.5) 2 (5.0) Mucosal inflammation 10 (12.0) 4 (4.8) 2 (5.0) Abdominal pain 9 (10.8) 2 (2.4) 2 (5.0) 1 (2.5) Diarrhea 7 (8.4) 1 (1.2) 7 (17.5) Abbreviations:, none reported in this category; AE, adverse event; TEAE, treatmentemergent AE. a Any given patient may have experienced more than one AE.

etable 3. Serious Adverse Events Occurring in Any Patient in Either Cohort Aldoxorubicin (n=83) Any SAE a, n (%) Study drugrelated SAE a,b, n (%) Any SAE a, n (%) Doxorubicin (n=40) Study drugrelated SAE a,b, n (%) 32 (38.6) 25 (30.1) 8 (20) 7 (17.5) BLOOD AND LYMPHATIC SYSTEM DISORDERS Febrile neutropenia 11 (13.3) 11 (13.3) 5 (12.5) 5 (12.5) Anemia 6 (7.2) 5 (6.0) 3 (7.5) 3 (7.5) Leukopenia 3 (3.6) 3 (3.6) Thrombocytopenia 2 (2.4) 2 (2.4) 1 (2.5) 1 (2.5) Neutropenia 1 (1.2) 1 (1.2) Pancytopenia 1 (1.2) 1 (1.2) Leukocytosis 1 (1.2) CARDIAC DISORDERS Atrial tachycardia 1 (1.2) Atrial fibrillation 1 (2.5) GASTROINTESTINAL DISORDERS Vomiting 3 (3.6) 3 (3.6) Stomatitis 2 (2.4) 2 (2.4) 1 (2.5) 1 (2.5) Gastritis 1 (1.2) 1 (1.2) Diarrhea 1 (1.2) 1 (2.5) 1 (2.5) Constipation 1 (1.2) Gastrointestinal hemorrhage 1 (1.2) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pyrexia 3 (3.6) 1 (1.2) Mucosal inflammation 1 (1.2) 1 (1.2) 1 (2.5) 1 (2.5) HEPATOBILIARY DISORDERS Cholecystitis 1 (1.2) Cholecystitis acute 1 (1.2) IMMUNE SYSTEM DISORDERS Hypersensitivity 1 (2.5) INFECTIONS AND INFESTATIONS Cellulitis 3 (3.6) Pneumonia 1 (1.2) 1 (1.2) 1 (2.5) 1 (2.5) Gastroenteritis 1 (1.2) 1 (1.2) Neutropenic sepsis 1 (1.2) 1 (1.2) Oral herpes 1 (1.2) 1 (1.2) Pertussis 1 (1.2) 1 (1.2) Urinary tract infection 1 (1.2) 1 (1.2) Lower respiratory tract infection 1 (1.2)

Septic shock 1 (2.5) 1 (2.5) Tooth infection 1 (2.5) METABOLISM AND NUTRITION DISORDERS Dehydration 1 (1.2) 1 (2.5) 1 (2.5) NEOPLASMS BENIGN, MALIGNANT, AND UNSPECIFIED Tumor hemorrhage 1 (1.2) NERVOUS SYSTEM DISORDERS Transient ischemic attack 1 (1.2) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Pleurisy 1 (1.2) Pulmonary embolism 1 (1.2) Pneumothorax 1 (2.5) VASCULAR DISORDERS Deep vein thrombosis 2 (2.4) Embolism 1 (1.2) 1 (1.2) Hypovolemic shock 1 (1.2) Abbreviations:, none reported in this category; SAE, serious adverse event. a Any given patient may have experienced more than 1 SAE. b Includes SAEs that are possibly or definitely related to study drug.

etable 4. Summary of Cardiac Events on Study Aldoxorubicin Doxorubicin Patients with ECHO or MUGA at baseline, n 82 a 39 a Median LVEF at baseline (range), % 60.5 (48.0-80.0) 63.0 (55.0-77.0) Patients with 10% drop in LVEF, by timepoint, n/n (%) Cycle 2 3/62 (4.8) 2/26 (7.7) Cycle 4 4/50 (8.0) 7/20 (35.0) Cycle 6 2/37 (5.4) 2/11 (18.2) End of treatment 1/51 (2.0) 4/26 (15.4) 2 months post-end of treatment 1/27 (3.7) 3/9 (33.3) 5 months post-end of treatment 0/16 1/3 (33.3) 8 months post-end of treatment 1/9 (11.1) 0/2 11 months post-end of treatment 0/6 0/0 Any cycle c 9/74 (12.2) 10/34 (29.4) Patients with LVEF 50%, n (% c ) 0/75 3/35 (8.6) Median (range) serum troponin, by timepoint, ng/ml Baseline 0.01 (0.00, 19.31) 0.01 (0.01, 3.79) Cycle 2 0.01 (0.00, 17.70) 0.01 (0.00, 17.75) Cycle 4 0.01 (0.00, 10.03) 0.02 (0.01, 37.70) Cycle 6 0.01 (0.01, 15.64) 0.08 (0.00, 85.59) End of treatment 0.01 (0.00, 23.83) 0.06 (0.00, 115.10) 2 months post-end of treatment 0.01 (0.00, 16.85) 0.02 (0.00, 24.91) 5 months post-end of treatment 0.01 (0.00, 0.01) 0.01 (0.00, 0.02) Abbreviations: ECHO, echocardiography; LVEF, left ventricular ejection fraction; MUGA, multigated acquisition scan. a One patient in each treatment arm had a nonnumeric baseline ECHO or MUGA value and was not included here. b Percent based on number of patients with at least 1 change from baseline value at any post-baseline cycle: aldoxorubicin (n=74) and doxorubicin (n=34). c Percent based on number of patients with at least 1 non-missing LVEF value at any postbaseline cycle: aldoxorubicin (n=75) and doxorubicin (n=35).